Search:
Filter:
Sort:
ADAP Advocacy and the Partnership for Safe Medicines (PSM) issued the following joint statement as a warning to pharmacists that all discounted HIV products bought from online, pharmacy-to-pharmacy (P2P) marketplaces fit the definition of suspect product under U.S. Food and Drug Administration (FDA) guidelines and the Drug Supply Chain Security Act.
The Partnership for Safe Medicines and ADAP Advocacy are warning that discounted HIV products bought from online, pharmacy-to-pharmacy (P2P) marketplaces qualify as suspicious products under U.S. Food and Drug Administration guidelines and the Drug Supply Chain Security Act. Given the risks, we believe that it isn’t safe or cost-effective to purchase HIV products from these platforms.
Americans have become accustomed to taking peptides for for improved health, but unless they’ve undergone clinical trials and received FDA approval, there’s no way to establish a peptide’s safety or effectiveness.
The internet is overrun with content promoting injectable weight loss medicines and there’s no way for viewers to know whether what they’re seeing is legitimate, genuine, safe, or true. Policymakers, social media platforms, and individuals can make changes to protect the public in this dangerous advertising environment.
United States District Court District of Nebraska USA v Peter Lam Complaint Filed June 2026 Read the document.
PMS’s new report outlines solutions to protect patient safety in the growing compounded GLP-1 marketplace. A Call to Action: Restoring and Strengthening America’s Patient Safety System serves as a roadmap for policymakers and regulators to uphold the gold standard system that protects Americans from untested and unsafe medicines.
PMS’s new report outlines solutions to protect patient safety in the growing compounded GLP-1 marketplace. A Call to Action: Restoring and Strengthening America’s Patient Safety System serves as a roadmap for policymakers and regulators to uphold the gold standard system that protects Americans from untested and unsafe medicines.
AFPs, which often force patients to source medicines overseas, may present access concerns according to a new study.
Photo gallery, Gilead Sciences v Pain Relief Rx et al Examples of suspect product purchased from pharmacy-to-pharmacy online platforms in December 2025 and January 2026.
Similar importation programs have been plagued with logistical hurdles, despite extensive funding of the efforts.